ArticleBMC medicine2018
Pancreatic cancer: challenges and opportunities.
Article in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 3 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.Neuro-oncology · 2023Pooled it
- A case-control study in Taiwanese cohort and meta-analysis of serum ferritin in pancreatic cancer.Scientific reports · 2021Pooled it
- Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer.International journal of medical sciences · 2021Pooled it
- Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.Scientific reports · 2023Trial
- Renal-clearable fluorescent probe for early detection of pancreatic cancer in living murine models.Science advances · 2026Article
- Synergistic Sensitization of Pancreatic Cancer Cells by Nanosecond Pulsed Electric Fields and Cold Atmospheric Plasma via Amplifying ROS and Apoptotic Signaling.International journal of molecular sciences · 2026Article
- Investigating the Impact of Curcumin on the Methylation of DNMT1, CDH1, SMG1, and WT1 Genes in the MIAPaCa2 Cell Line Using High-Resolution Melting Analysis Compared to Methylation-Specific PCR.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study.Gastroenterology report · 2026Article
- Astragaloside IV promotes the apoptosis of pancreatic cancer cells by activating endoplasmic reticulum stress through the PERK/ATF4/CHOP signaling pathway.Molecular medicine reports · 2026Article
- The Proteome of African Spitting and Non-Spitting Cobra Venoms and Cytotoxicity Against Pancreatic Cancer Cells.Journal of applied toxicology : JAT · 2025Article
- Interferon-α and thymosin-α1 plus tislelizumab enhance CD8iScience · 2025Article
- Review
- CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization.Cell death and differentiation · 2025Article
- USP39: a key regulator in malignant tumor progression.Frontiers in oncology · 2025Review
- MDMU-Net: 3D multi-dimensional decoupled multi-scale U-Net for pancreatic cancer segmentation.PeerJ. Computer science · 2025Article
- PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B.Medical oncology (Northwood, London, England) · 2024Article
- RRM2 promotes liver metastasis of pancreatic cancer by stabilizing YBX1 and activating the TGF-beta pathway.iScience · 2024Article
- Incidence Rates and Time Trends of Pancreatic Cancer in the Golestan Province, Northeastern Iran, 2006-2019.Archives of Iranian medicine · 2024Article
- The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy.International journal of molecular sciences · 2024Article
- DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.Cancer immunology, immunotherapy : CII · 2024Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with increasing incidence. The mortality rate of pancreatic cancer is rising rapidly, and is projected to be the second most common of all malignant tumors by 2030. However, the diagnosis and therapy of pancreatic cancer remain a formidable challenge. Recently, enormous efforts have been made to develop several new methods for the early diagnosis and treatment of pancreatic cancer. We briefly introduce the most groundbreaking advances in pancreatic cancer diagnosis and clinical treatment strategies over the past 15 years, including surgery, chemotherapy, endoscopic therapy, immunotherapy and personalized medicine. The signaling pathways that are altered in the progression of pancreatic cancer, which may be used as therapeutic targets, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.